EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Advances of the “Miracle Protein” Against Viral Diseases: Lactoferrin in Clinical Trials

Gerardo Ramírez-Rico, Lucero Ruiz Mazón, Magda Reyes-López, Jesús Serrano Lúna, Christian Avalos Gómez, Rosa Isabel Higuera Piedrahita, Cristal Dafne Lonngi Sosa, Mireya de la Garza, Cynthia González Ruíz

Future Pharmacology · 13.03.2026 · 6 (1) · 14

DOI: 10.3390/futurepharmacol6010014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Pharmacology, online erschienen am 13.03.2026. Verfasst von Gerardo Ramírez-Rico und 8 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Programa de Apoyo a Proyectos de Investigación e Innovación Tecnológica, COMECYT-CIKAS.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antimicrobial resistance is a significant problem that has been studied in recent years. Viral diseases have generated high levels of morbidity and mortality, and recently, the world population faced a highly contagious viral disease (SARS-CoV-2), which caused millions of deaths without an effective drug capable of controlling the infectious process. As a result, various therapeutic alternatives to antimicrobials have emerged that target microorganisms, support the immune system, and reduce inflammation. Lactoferrin is a ultifunctional glycoprotein of the mammalian innate immune system that has shown various benefits, notably its antimicrobial and, primarily, its antiviral effects. No resistance or toxicity to this protein has been reported, which is why it is called a “miracle protein”. This is the first review to focus on the antiviral effects of lactoferrin in clinical trials. In addition, in vitro and in vivo studies evaluating lactoferrin against various viral etiologies are also discussed.

Förderung

  • Programa de Apoyo a Proyectos de Investigación e Innovación Tecnológica
  • COMECYT-CIKAS

Zitieren

APA

Ramírez-Rico, G., Mazón, L. R., Reyes-López, M., Lúna, J. S., Gómez, C. A., Piedrahita, R. I. H., Sosa, C. D. L., Garza, M. D. L., & Ruíz, C. G. (2026). Advances of the “Miracle Protein” Against Viral Diseases: Lactoferrin in Clinical Trials. Future Pharmacology, 6(1), 14. https://doi.org/10.3390/futurepharmacol6010014

Vancouver

Ramírez-Rico G, Mazón LR, Reyes-López M, Lúna JS, Gómez CA, Piedrahita RIH, et al. Advances of the “Miracle Protein” Against Viral Diseases: Lactoferrin in Clinical Trials. Future Pharmacology. 2026;6(1):14. doi:10.3390/futurepharmacol6010014

BibTeX
@article{RamrezRico2026,
  author = {Ramírez-Rico, Gerardo and Mazón, Lucero Ruiz and Reyes-López, Magda and Lúna, Jesús Serrano and Gómez, Christian Avalos and Piedrahita, Rosa Isabel Higuera and Sosa, Cristal Dafne Lonngi and Garza, Mireya de la and Ruíz, Cynthia González},
  title = {Advances of the “Miracle Protein” Against Viral Diseases: Lactoferrin in Clinical Trials},
  journal = {Future Pharmacology},
  year = {2026},
  volume = {6},
  number = {1},
  pages = {14},
  doi = {10.3390/futurepharmacol6010014}
}
Kostenlos starten →